Back to Report Store Home

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 – Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

  • Published: Nov-2018
  • Report Code: GBIHC485MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 11

2.1 Disease Introduction 11

2.2 Epidemiology 11

2.3 Symptoms 12

2.4 Etiology and Pathophysiology 13

2.4.1 Etiology 13

2.4.2 Pathophysiology 14

2.5 Diagnosis 15

2.5.1 Hanifin and Rajka Diagnostic Criteria 15

2.5.2 UK Working Party’s Diagnostic Criteria 16

2.5.3 Biomarkers 16

2.6 Classification and Disease Stages 16

2.7 Prognosis 17

2.8 Treatment Options and Guidelines 17

2.8.1 Emollients 17

2.8.2 Topical corticosteroids 17

2.8.3 Topical calcineurin inhibitors 17

2.8.4 Antimicrobials 18

2.8.5 Systemic immunosuppressive therapy 18

2.8.6 Biologics 18

2.8.7 Other treatments 18

2.8.8 Wet wrap therapy 18

2.9 Treatment guidelines 19

3 Marketed Products 21

3.1 Overview 21

3.1.1 Dupixent (dupilumab) – Regeneron and Sanofi 21

3.1.2 Protopic (tacrolimus) – Astellas 23

3.1.3 Elidel (Pimecrolimus) – Novartis 25

3.1.4 Cyclosporine 26

3.1.5 Xolair (omalizumab) – Novartis and Genentech (Off-Label Therapy) 27

3.1.6 Eucrisa (crisaborole) – Pfizer 28

3.1.7 Other Therapeutic Drug Classes Used in Atopic Dermatitis 29

3.2 Comparative Efficacy and Safety of Marketed Products 30

4 Pipeline Analysis 33

4.1 Overview 33

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 34

4.3 Pipeline by Molecular Target 36

4.4 Promising Pipeline Candidates 38

4.4.1 Tralokinumab – LEO Pharma 38

4.4.2 Furestem-AD – Kang Stem Biotech 39

4.4.3 Baricitinib – Eli Lilly and Incyte Corporation 41

4.4.4 PAC-14028– Amorepacific 42

4.4.5 PF-04965842 – Pfizer 43

4.5 Comparative Efficacy and Safety of Pipeline Products 43

4.6 Product Competitiveness Framework 45

5 Clinical Trial Analysis 47

5.1 Failure Rate 47

5.1.1 Overall Failure Rate 47

5.1.2 Failure Rate by Phase and Molecule Type 48

5.1.3 Failure Rate by Phase and Molecule Target 49

5.2 Clinical Trial Size 50

5.2.1 Patient Enrollment per Trial by Molecule Type and Stage of Development 50

5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 51

5.2.3 Patient Enrollment per Product by Molecule Type and Stage of Development 52

5.2.4 Patient Enrollment per Product by Molecular Target and Stage of Development 53

5.3 Clinical Trial Duration 54

5.3.1 Clinical Trial Duration by Molecule Type 54

5.3.2 Clinical Trial Duration by Molecular Target 55

5.4 Competitive Clinical Trials Metrics Analysis 56

6 Multi-scenario Forecast 58

6.1 Geographical Market 58

6.2 Southeast Asian Markets 58

6.3 South Korea 61

6.3.1 Treatment Usage Patterns 61

6.3.2 Annual Cost of Therapy 62

6.3.3 Market Size 63

6.4 Singapore 64

6.4.1 Treatment Usage Patterns 64

6.4.2 Annual Cost of Therapy 65

6.4.3 Market Size 66

6.5 Taiwan 67

6.5.1 Treatment Usage Patterns 67

6.5.2 Annual Cost of Therapy 68

6.5.3 Market Size 69

6.6 Malaysia 70

6.6.1 Treatment Usage Patterns 70

6.6.2 Annual Cost of Therapy 71

6.6.3 Market Size 72

6.7 Philippines 73

6.7.1 Treatment Usage Patterns 73

6.7.2 Annual Cost of Therapy 73

6.7.3 Market Size 74

6.8 Thailand 75

6.8.1 Treatment Usage Patterns 75

6.8.2 Annual Cost of Therapy 76

6.8.3 Market Size 77

6.9 Vietnam 78

6.9.1 Treatment Usage Patterns 78

6.9.2 Annual Cost of Therapy 79

6.9.3 Market Size 80

6.10 Indonesia 80

6.10.1 Treatment Usage Patterns 80

6.10.2 Annual Cost of Therapy 81

6.10.3 Market Size 82

7 Drivers and Barriers 84

7.1 Drivers 84

7.1.1 Increasing awareness and diversified healthcare reform to boost market growth 84

7.1.2 Promising pipeline products that target unmet needs for AD 84

7.1.3 Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 84

7.2 Barriers 85

7.2.1 First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 85

7.2.2 Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 85

7.2.3 The complexity of the multiple etiologies that lead to AD means that treatment outcomes with existing drugs are not universal across all patient groups 85

8 Deals and Strategic Consolidations 86

8.1 Licensing Deals 86

8.1.1 Deals by Region and Value 86

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 87

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87

8.1.4 Key Licensing Deals 90

8.2 Co-development Deals 91

8.2.1 Deals by region, value, year, stage of development, molecule type and molecular target 91

8.2.2 Key Co-development Deals 92

9 Appendix 93

9.1 All Pipeline Drugs by Stage of Development 93

9.1.1 Discovery 93

9.1.2 Preclinical 94

9.1.3 Phase I 96

9.1.4 Phase II 97

9.1.5 Phase III 98

9.2 Summary of Multi-Scenario Market Forecasts to 2024 99

9.2.1 Southeast Asia 99

9.2.2 South Korea 99

9.2.3 Singapore 100

9.2.4 Taiwan 100

9.2.5 Malaysia 101

9.2.6 Philippines 101

9.2.7 Thailand 102

9.2.8 Vietnam 102

9.2.9 Indonesia 103

9.3 Bibliography 103

9.4 Abbreviations 108

9.5 Research Methodology 109

9.5.1 Secondary Research 110

9.5.2 Marketed Product Profiles 110

9.5.3 Late-Stage Pipeline Candidates 110

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 110

9.5.5 Product Competitiveness Framework 111

9.5.6 Pipeline Analysis 111

9.5.7 Forecasting Model 111

9.5.8 Deals Data Analysis 112

9.6 Contact Us 113

9.7 Disclaimer 113

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards